Previous Close | 2.4200 |
Open | 2.4200 |
Bid | 0.0000 x 800 |
Ask | 0.0000 x 1800 |
Day's Range | 2.3800 - 2.4550 |
52 Week Range | 1.7950 - 4.5000 |
Volume | |
Avg. Volume | 840,904 |
Market Cap | 317.775M |
Beta (5Y Monthly) | 1.42 |
PE Ratio (TTM) | 30.25 |
EPS (TTM) | 0.0800 |
Earnings Date | Nov 07, 2023 - Nov 13, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for ORGO
CANTON, Mass. , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that company management will participate in the Morgan Stanley 21st Annual Global Healthcare Conference, which is being held at the Sheraton New York Times Square Hotel in New York, NY from Septemb
Shares of Organogenesis Holdings (NASDAQ: ORGO) were down more than 19% as of 11 a.m. on Thursday after the company announced second-quarter earnings and withdrew annual guidance after the markets closed on Wednesday. Organogenesis is a healthcare company that makes advanced care products for the wound-healing process. The company operates in two segments, Advanced Wound Care and Surgical & Sports Medicine, and both saw declines.
Q2 2023 Organogenesis Holdings Inc Earnings Call